Preclinical Models of Cancer Therapy–Associated Cardiovascular Toxicity
Published: May 03, 2021
- Traditional and novel chemotherapies for cancer have cardiovascular sequelae, driving the emergence of cardio-oncology as a clinical and research field.
- Preclinical research models provide a means to determine the molecular mechanisms of cardiovascular toxicity that will facilitate the optimal use of cancer treatments.
- In the rapidly expanding field of cardio-oncology, continuing development and evaluation of preclinical research models help understand how novel cancer therapies impact the cardiovascular system.